Kidney Disease & Nephrology Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

FXS6837 for the Treatment for IgAN Patients（Longterm Study）

This Phase 2 study is testing the long-term safety and effectiveness of FXS6837 capsules in patients with primary IgA nephropathy, a common kidney disease that can lead to kidney failure. The trial is taking place in China and involves about 60 patients who previously took part in an earlier FXS6837 study, with treatment lasting two years. If successful, this oral medication could offer a new option for managing IgA nephropathy, potentially helping patients maintain better kidney health over time.

Community-Based Screening for Chronic Kidney Disease

This study focuses on screening people at risk for chronic kidney disease and high blood pressure in trusted community settings in the United States. By identifying kidney problems early and referring patients for kidney-protective care, the study aims to slow down kidney damage and improve health outcomes. With 145 participants, this approach could bring important kidney health services closer to the community and catch disease sooner.

DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients

This study is looking at blood levels of two markers, DEL-1 and thromboxane A2, in patients with diabetic kidney disease and healthy volunteers. Understanding how these markers relate to disease progression may help doctors better diagnose and monitor kidney problems caused by diabetes. The trial plans to enroll 80 participants and hopes to provide insight that could lead to improved care for people with diabetic nephropathy.

Perioperative Transcutaneous Fluorescence Detection of GFR Trajectory for the Early Prediction and Diagnosis of CSA-AKI.

This study is testing a new method that uses fluorescence to monitor kidney function during heart-related surgeries in China. The goal is to detect acute kidney injury earlier than current methods allow. Early detection during surgery could help doctors manage kidney health more proactively and improve recovery after cardiovascular procedures.

Impact of Intraoperative Blood Pressure Components on Postoperative AKI: A Phenotype-Stratified Analysis

This research analyzes over 44,000 surgery records in China to better understand how blood pressure during non-heart surgeries affects the risk of acute kidney injury after surgery. The study aims to develop personalized blood pressure targets to protect kidney health for each patient. Although not currently recruiting, this work could lead to safer surgery practices and fewer kidney complications.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.